BRAF inhibitors have demonstrated a substantial degree of efficacy in the treatment of patients with melanoma carrying BRAF V600 mutations [45]; however, as is the case with other chemotherapeutic agents, resistance development constrains the clinical utility of these drugs. Here, BRAF is linked to melanoma.